In a group of NSCLC patients undergoing treatment with durvalumab, those with increased expression levels of genes encoding IFNγ, CD274, LAG3, and CXCL9 were defined as IFN-γ+. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.